Details 265 Trials 40 Therapies

A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)

synonyms
synonyms
Myeloma
synonyms
myelomatosis
synonyms
Myeloma, NOS
synonyms
Kahler disease
synonyms
Multiple Myeloma
synonyms
Plasma Cell Myeloma
synonyms
Bone marrow multiple myeloma
synonyms
MYELOMA, PLASMA CELL, MALIGNANT
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
city
134 sites for NCT05083169
condition
Multiple Myeloma
drug
bortezomib, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
city
129 sites for NCT04923893
condition
Multiple Myeloma
drug
bortezomib, +5 more drugs
drug type
cellular therapy, +4 more types
Show 265 Trials for Multiple Myeloma
Show 40 Therapies for Multiple Myeloma